PL3935068T3 - Proleki abirateronu - Google Patents
Proleki abirateronuInfo
- Publication number
- PL3935068T3 PL3935068T3 PL20717363.4T PL20717363T PL3935068T3 PL 3935068 T3 PL3935068 T3 PL 3935068T3 PL 20717363 T PL20717363 T PL 20717363T PL 3935068 T3 PL3935068 T3 PL 3935068T3
- Authority
- PL
- Poland
- Prior art keywords
- abiraterone
- prodrugs
- abiraterone prodrugs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814568P | 2019-03-06 | 2019-03-06 | |
| US201962849259P | 2019-05-17 | 2019-05-17 | |
| PCT/US2020/020915 WO2020180942A1 (en) | 2019-03-06 | 2020-03-04 | Abiraterone prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3935068T3 true PL3935068T3 (pl) | 2024-02-26 |
Family
ID=70190090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20717363.4T PL3935068T3 (pl) | 2019-03-06 | 2020-03-04 | Proleki abirateronu |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10792292B2 (pl) |
| EP (2) | EP4286006A3 (pl) |
| JP (1) | JP7644713B2 (pl) |
| KR (1) | KR102879575B1 (pl) |
| CN (3) | CN120484046A (pl) |
| AU (1) | AU2020232706B2 (pl) |
| BR (1) | BR112021017377A2 (pl) |
| CA (1) | CA3131034A1 (pl) |
| DK (1) | DK3935068T3 (pl) |
| ES (1) | ES2964818T3 (pl) |
| IL (1) | IL286048B2 (pl) |
| MX (1) | MX2021010553A (pl) |
| PL (1) | PL3935068T3 (pl) |
| WO (1) | WO2020180942A1 (pl) |
| ZA (1) | ZA202107278B (pl) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3935068T3 (pl) * | 2019-03-06 | 2024-02-26 | Propella Therapeutics, Inc. | Proleki abirateronu |
| US12347562B2 (en) * | 2019-12-26 | 2025-07-01 | Cerner Innovation, Inc. | Decision support application for PCOS |
| EP4208171A1 (en) * | 2020-09-02 | 2023-07-12 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
| CN113929727A (zh) * | 2020-09-28 | 2022-01-14 | 南京易腾药物研究院有限公司 | 阿比特龙酯类衍生物及其制备方法和应用 |
| US11957696B2 (en) * | 2021-02-15 | 2024-04-16 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
| CN113061154B (zh) * | 2021-03-25 | 2022-07-08 | 天津海润家和创新医药研究有限责任公司 | 新型注射用阿比特龙衍生物的制备方法和用途 |
| CN113527401A (zh) * | 2021-08-26 | 2021-10-22 | 雷昊言 | 一种阿比特龙前体化合物及其制备方法和应用 |
| JP2024533332A (ja) * | 2021-09-08 | 2024-09-12 | プロペラ セラピューティクス インコーポレイテッド | 経口アビラテロン製剤 |
| IL315174A (en) * | 2022-03-01 | 2024-10-01 | Propella Therapeutics Inc | Abiraterone decanoate drug metrics and treatment use |
| WO2024107928A1 (en) * | 2022-11-16 | 2024-05-23 | Propella Therapeutics, Inc. | Abiraterone decanoate composition and use in therapy |
| CN116046950A (zh) * | 2023-01-18 | 2023-05-02 | 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) | 一种检测醋酸阿比特龙中5种杂质的方法 |
| LU506495B1 (en) * | 2024-03-01 | 2025-09-01 | Alfasan Nederland B V | 17alpha-HYDROXYLASE/17,20-LYASE (CYP17A1) INHIBITORS FOR THE TREATMENT OF SPONTANEOUS HYPERADRENOCORTICISM IN DOGS |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604213A (en) | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
| CA2478827A1 (en) | 2002-03-11 | 2003-09-18 | Takeda Chemical Industries, Ltd. | Remedies for sex hormone-dependent disease |
| JP2004002321A (ja) * | 2002-03-11 | 2004-01-08 | Takeda Chem Ind Ltd | 性ホルモン依存性疾患治療剤 |
| TW200404552A (en) | 2002-05-30 | 2004-04-01 | Akzo Nobel Nv | Self administered contraception |
| GB0418900D0 (en) | 2004-08-24 | 2004-09-29 | Btg Int Ltd | Novel salt forms |
| JP5235662B2 (ja) * | 2005-06-16 | 2013-07-10 | ミリアド ジェネティクス， インコーポレイテッド | 薬学的組成物およびその使用 |
| US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| SI2061561T1 (sl) * | 2006-08-25 | 2013-11-29 | Janssen Oncology, Inc. | Sestavki za zdravljenje raka |
| US20090124587A1 (en) | 2007-07-12 | 2009-05-14 | Auerbach Alan H | METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS |
| US20110312916A1 (en) | 2009-02-05 | 2011-12-22 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
| GB2479693B (en) | 2009-02-05 | 2014-04-09 | Tokai Pharmaceuticals Inc | Steroidal CYP17 inhibitors and their use in the treatment of cancer and prostate hyperplasia |
| US20110129423A1 (en) | 2009-11-30 | 2011-06-02 | Frincke James M | Anticancer compounds and screening method |
| JPWO2011083830A1 (ja) * | 2010-01-06 | 2013-05-16 | 学校法人関西文理総合学園 | 新規抗がん剤およびそのスクリーニング方法 |
| TW201307378A (zh) | 2010-12-16 | 2013-02-16 | Biomarin Pharm Inc | Ｃｙｐ１１ｂ、ｃｙｐ１７及／或ｃｙｐ２１抑制劑 |
| DE102011083725A1 (de) | 2011-09-29 | 2013-04-04 | Bayer Pharma AG | Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln |
| CA2851330C (en) | 2011-10-10 | 2019-07-16 | Zach System | Process for preparing 17-substituted steroids |
| SG11201401471PA (en) | 2011-11-30 | 2014-08-28 | Astrazeneca Ab | Combination treatment of cancer |
| CA2859986A1 (en) | 2011-12-22 | 2013-06-27 | Tokai Pharmaceuticals, Inc. | Methods and compositions for combination therapy using pi3k/mtor inhibitors |
| US20140079636A1 (en) | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
| CA2871314A1 (en) | 2012-04-23 | 2013-10-31 | Alphora Research Inc. | Process for preparation of 17-substituted steroids |
| WO2014009434A1 (en) | 2012-07-11 | 2014-01-16 | Sandoz Ag | Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate |
| EP2877482A4 (en) | 2012-07-25 | 2016-04-06 | Mapi Pharma Ltd | PROCESS AND INTERMEDIATES USED IN THE PREPARATION OF ABIRATERONE ACETATE |
| US20140011992A1 (en) | 2012-12-20 | 2014-01-09 | Crystal Pharma, S.A.U. | Synthesis of abiraterone and related compounds |
| LT2945628T (lt) | 2013-01-15 | 2020-05-25 | Aragon Pharmaceuticals, Inc. | Androgeno receptoriaus moduliatorius derinyje su abiraterono acetatu ir prednizonu, skirtas prostatos vėžio gydymui |
| CA2898573A1 (en) | 2013-01-18 | 2014-07-24 | Cortendo Ab (Publ) | Abiraterone and analogs thereof for the treatment of diseases associated with cortisol overproduction |
| PL3578266T3 (pl) | 2013-03-15 | 2024-10-21 | Sun Pharmaceutical Industries Limited | Formulacja octanu abirateronu |
| US20150246060A1 (en) | 2013-03-15 | 2015-09-03 | Iceutica Inc. | Abiraterone Acetate Formulation and Methods of Use |
| EP3035938B1 (en) | 2013-09-10 | 2020-08-19 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
| US20150157646A1 (en) | 2013-09-27 | 2015-06-11 | Iceutica Inc. | Abiraterone Steroid Formulation |
| BR112016006976A2 (pt) | 2013-10-01 | 2017-08-01 | Novartis Ag | combinação |
| AU2015224576A1 (en) | 2014-03-03 | 2016-09-22 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
| EP3131586A4 (en) | 2014-03-18 | 2017-10-25 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
| CN104017045B (zh) * | 2014-06-23 | 2016-01-13 | 广州艾格生物科技有限公司 | 甾体cyp17抑制剂的新型药物前体及其应用、制备方法 |
| WO2015200837A1 (en) * | 2014-06-27 | 2015-12-30 | Fl Therapeutics Llc | Abiraterone derivatives and non-covalent complexes with albumin |
| MX2017003525A (es) | 2014-09-18 | 2017-06-21 | Iceutica Inc | Formulacion de acetato de abiraterona y metodos de uso. |
| CN104356191A (zh) | 2014-09-29 | 2015-02-18 | 上海延安药业（湖北）有限公司 | 阿比特龙单琥珀酸酯及其制备方法 |
| CN105646637B (zh) | 2014-11-28 | 2018-12-14 | 四川海思科制药有限公司 | 一种阿比特龙衍生物及其制备方法和医药用途 |
| CN104447394B (zh) * | 2014-12-17 | 2017-01-18 | 成都傲飞生物化学品有限责任公司 | 一种乌苯美司的新型合成工艺 |
| CN104710499A (zh) * | 2015-02-15 | 2015-06-17 | 重庆医药工业研究院有限责任公司 | 一种丙酸阿比特龙的晶型及其制备方法 |
| BR112017018758A2 (pt) * | 2015-03-06 | 2018-04-17 | Cleveland Clinic Found | alteração do metabolismo de esteroide para tratamento de doença dependente de esteroide |
| WO2017106957A1 (en) * | 2015-12-23 | 2017-06-29 | The University Of British Columbia | Lipid-linked prodrugs |
| US10519193B2 (en) | 2016-02-02 | 2019-12-31 | Shenzhen Targetrx, Inc. | Steroidal compound, composition containing the same and use thereof |
| MA45052A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille |
| WO2018071544A1 (en) | 2016-10-11 | 2018-04-19 | Zhuhai Beihai Biotech Co., Ltd. | Abiraterone derivative and formulations thereof |
| CN106977577A (zh) | 2017-04-21 | 2017-07-25 | 湖南师范大学 | 两类阿比特龙衍生物的合成 |
| JP2022523704A (ja) | 2019-01-25 | 2022-04-26 | シェンチェン・ファーマシン・カンパニー・リミテッド | 医薬組成物 |
| PL3935068T3 (pl) | 2019-03-06 | 2024-02-26 | Propella Therapeutics, Inc. | Proleki abirateronu |
| JP2022525425A (ja) | 2019-03-18 | 2022-05-13 | ディスパーソル テクノロジーズ リミテッド ライアビリティ カンパニー | アビラテロン－環状オリゴマー薬学的製剤ならびにその形成方法および投与方法 |
| EP4208171A1 (en) | 2020-09-02 | 2023-07-12 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
| CN113929727A (zh) | 2020-09-28 | 2022-01-14 | 南京易腾药物研究院有限公司 | 阿比特龙酯类衍生物及其制备方法和应用 |
| US11957696B2 (en) | 2021-02-15 | 2024-04-16 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
| JP2024533332A (ja) | 2021-09-08 | 2024-09-12 | プロペラ セラピューティクス インコーポレイテッド | 経口アビラテロン製剤 |
-
2020
- 2020-03-04 PL PL20717363.4T patent/PL3935068T3/pl unknown
- 2020-03-04 WO PCT/US2020/020915 patent/WO2020180942A1/en not_active Ceased
- 2020-03-04 ES ES20717363T patent/ES2964818T3/es active Active
- 2020-03-04 MX MX2021010553A patent/MX2021010553A/es unknown
- 2020-03-04 CN CN202510025122.4A patent/CN120484046A/zh active Pending
- 2020-03-04 DK DK20717363.4T patent/DK3935068T3/da active
- 2020-03-04 CA CA3131034A patent/CA3131034A1/en active Pending
- 2020-03-04 EP EP23188119.4A patent/EP4286006A3/en active Pending
- 2020-03-04 JP JP2021552742A patent/JP7644713B2/ja active Active
- 2020-03-04 AU AU2020232706A patent/AU2020232706B2/en active Active
- 2020-03-04 CN CN202080032112.9A patent/CN114026106B/zh active Active
- 2020-03-04 BR BR112021017377A patent/BR112021017377A2/pt unknown
- 2020-03-04 KR KR1020217032021A patent/KR102879575B1/ko active Active
- 2020-03-04 US US16/808,912 patent/US10792292B2/en active Active
- 2020-03-04 IL IL286048A patent/IL286048B2/en unknown
- 2020-03-04 CN CN202510025166.7A patent/CN120531742A/zh active Pending
- 2020-03-04 EP EP20717363.4A patent/EP3935068B1/en active Active
- 2020-08-10 US US16/989,304 patent/US11559534B2/en active Active
-
2021
- 2021-09-28 ZA ZA2021/07278A patent/ZA202107278B/en unknown
-
2023
- 2023-01-19 US US18/098,798 patent/US12138273B2/en active Active
-
2024
- 2024-10-18 US US18/920,358 patent/US20250099489A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200281945A1 (en) | 2020-09-10 |
| EP3935068A1 (en) | 2022-01-12 |
| US20250099489A1 (en) | 2025-03-27 |
| EP3935068B1 (en) | 2023-09-06 |
| CN114026106A (zh) | 2022-02-08 |
| KR102879575B1 (ko) | 2025-11-03 |
| US12138273B2 (en) | 2024-11-12 |
| AU2020232706B2 (en) | 2025-10-02 |
| JP2022523819A (ja) | 2022-04-26 |
| EP4286006A2 (en) | 2023-12-06 |
| IL286048B2 (en) | 2025-03-01 |
| US20200368255A1 (en) | 2020-11-26 |
| CN120531742A (zh) | 2025-08-26 |
| IL286048B1 (en) | 2024-11-01 |
| ES2964818T3 (es) | 2024-04-09 |
| ZA202107278B (en) | 2023-06-28 |
| US11559534B2 (en) | 2023-01-24 |
| CN120484046A (zh) | 2025-08-15 |
| EP4286006A3 (en) | 2024-03-20 |
| US10792292B2 (en) | 2020-10-06 |
| US20230233582A1 (en) | 2023-07-27 |
| IL286048A (en) | 2021-10-31 |
| JP7644713B2 (ja) | 2025-03-12 |
| CA3131034A1 (en) | 2020-09-10 |
| CN114026106B (zh) | 2025-01-21 |
| BR112021017377A2 (pt) | 2021-11-16 |
| AU2020232706A1 (en) | 2021-09-16 |
| KR20210136072A (ko) | 2021-11-16 |
| DK3935068T3 (da) | 2023-12-04 |
| MX2021010553A (es) | 2021-12-15 |
| WO2020180942A1 (en) | 2020-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202107278B (en) | Abiraterone prodrugs | |
| DK3958977T3 (en) | Camptothecinderivater | |
| CA196372S (en) | Soundbar | |
| DK4119172T3 (en) | Automatisk injektionssystem | |
| DK3980417T3 (en) | PRMT5-Inhibitorer | |
| DK3942152T3 (en) | Tætninger | |
| CA191618S (en) | Floorwasher - nozzle | |
| GB201901778D0 (en) | Aladin | |
| CA201154S (en) | Banquette | |
| GB202204160D0 (en) | Brackets | |
| CA189677S (en) | Uroflowmeter | |
| CA190552S (en) | Hand-dryer | |
| CA189795S (en) | Handshower | |
| PT3360866T (pt) | Pró-fármacos de mirabegrom | |
| CA190386S (en) | Beverageware | |
| CA189047S (en) | Hammock-tent | |
| CA190385S (en) | Beverageware | |
| CA190387S (en) | Beverageware | |
| CA190384S (en) | Beverageware | |
| GB201903873D0 (en) | Enhanced transfection | |
| GB201900347D0 (en) | Blazeloc | |
| GB2588486B (en) | Former | |
| GB201808537D0 (en) | Prodrugs | |
| DK3832828T3 (en) | Strømforyningsnetsystem | |
| CA192228S (en) | Hydrogenerator |